Efficacy and Tolerability of New Topical Formulations in Subjects With Atopic Dermatitis

This is a 13 week randomized, double blind, parallel group, in home use study among approximately 60 male and female subjects, ages 12 to 65 years old inclusive, with atopic dermatitis (AD) SCORAD >16. Treatment group assignments will be balanced by disease severity, age, and body location of AD lesions. The study will consist of a 1 week washout phase and 12 week treatment phase. During the washout phase, subjects will be provided with a bar soap for bathing and showering and must refrain from using any other products on their body (excluding the face) including topical corticosteroids, ointments, lotions, sunscreens, etc. During the treatment phase, subjects will be randomized to 1 of 4 test legs. Throughout the treatment phase, the subjects will be required to use only the provided bar soap for bathing and showering and will apply their test product twice per day, once in the morning and once in the evening. No additional creams, moisturizers, lotions or cleansers other than those provided will be permitted for the duration of the study. Normal facial or hair care products are permitted, however, they must not contain anti-bacterial ingredients (e.g. antidandruff shampoo, acne products, etc).

SCORAD, EASI and PGA will incorporate whole body assessments. However, at the Baseline visit, subjects will have an active inflammatory lesion site and adjacent non-lesion, non-inflammatory site identified and marked for all instrumental and biopsy evaluations at Baseline and subsequent visits. Instrumental evaluations, imaging, expert visual grading and self-assessments will be performed throughout the study. Tolerability will be evaluated by incidence of AE's (defined per CTCAE), exacerbation of AD lesions, application site reactions/infections, and lab evaluations throughout the study. There will be additional consumption and compliance checks as well as dermatologic evaluations to ensure the subject's condition does not become extensively worse at each visit. A subset of subjects will have 2mm punch biopsies collected from the designated lesion and non-lesion sites at 3 time points throughout the study. The subset of subjects will be determined by subject willingness to participate in the biopsy portion as well as dermatologic evaluation and determination of biopsy candidacy.

Study Overview

• Status: Completed
• Conditions: Eczema; Dermatitis, Atopic
• Intervention / Treatment: Drug: Investigational OTC Cream; Other: Placebo Cream; Other: Cosmetic Eczema Cream; Drug: 0.05% Desonide Cream

• Study Type: Interventional
• Enrollment (Actual): 53
• Phase: Phase 4

Contacts and Locations

Study Locations

• United States
  • North Carolina
    • Raleigh, North Carolina, United States, 27612
      • Wake Research Associates, LLC

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 12 years to 65 years (ADULT, OLDER_ADULT, CHILD)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

Description

Inclusion Criteria:

• Is a generally healthy, male or female, 12-65 years old, inclusive
• Diagnosis of moderate or greater Atopic Dermatitis as determined by the Physician's Global Assessment (PGA of 3 or 4)

Exclusion Criteria:

• Is currently participating or has participated in another interventional clinical study at this or any other facility in the past 2 weeks
• Currently or has been diagnosed or treated for cancer in the past 5 years.
• Requires any topical or systemic medications that could affect the course of their atopic dermatitis during the study period (except inhaled steroids and/or stable antihistamines for asthma or allergies).
• Has a known hypersensitivity to any corticosteroid creams.
• Has a known sensitivity to Epinephrine, Xylocaine or topical antibiotics.
• Has a wound healing or blood-clotting abnormality.
• Has any active infections or has used antibiotics in the past 7 days.
• Has any physical attributes or skin conditions that might interfere with the clear visual or instrumental assessments.(i.e. cuts, sunburn, birth marks, tattoos, extensive scarring, excessive hair growth or acne)
• Has an immunologic or infectious disease (e.g. hepatitis, tuberculosis, HIV or AIDS, lupus rheumatoid arthritis) which could place the subject at risk or interfere with the accuracy of the study results.
• Has used any immunosuppressant drugs or immunotherapy within the past 30 days or 5 half-lives.
• Is an employee of the Sponsor Company or clinical testing site.
• Is diabetic.
• Is dependent on oral medication for any skin disease/condition or could not, in the opinion of the Investigator tolerate the restriction of discontinuing the medicine as required in this study.
• Is currently pregnant or lactating or planning to become pregnant in the next 6 months.
• Has a history of keloid formation following skin injury.
• Is routinely taking anti-coagulant medications (i.e. Plavix, Coumadin, warfarin, heparin, etc.)
• Any other condition or factor the Investigator or their duly assigned representative believes may affect the ability of the subject to complete the study or the interpretation of the results.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: TREATMENT
• Allocation: RANDOMIZED
• Interventional Model: PARALLEL
• Masking: TRIPLE

Number of Arms

4

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
EXPERIMENTAL: Investigational OTC Cream; Investigational OTC Cream applied topically, twice daily, for 12 weeks, once in the morning and once in the evening, to atopic dermatitis lesions and anywhere else the patient would apply their ordinary body moisturizer.	Drug: Investigational OTC Cream
PLACEBO_COMPARATOR: Placebo Cream; Placebo Cream applied topically, twice daily, for 12 weeks, once in the morning and once in the evening, to atopic dermatitis lesions and anywhere else the patient would apply their ordinary body moisturizer.	Other: Placebo Cream
ACTIVE_COMPARATOR: Cosmetic Eczema Cream; Cosmetic Eczema Cream applied topically, twice daily, for 12 weeks, once in the morning and once in the evening, to atopic dermatitis lesions and anywhere else the patient would apply their ordinary body moisturizer.	Other: Cosmetic Eczema Cream; Other Names: CeraVe
ACTIVE_COMPARATOR: 0.05% Desonide Cream; Rx Steroid applied topically, twice daily, once in the morning and once in the evening, for 4 weeks to atopic dermatitis lesions and then on any new lesions that appear for 4 weeks and as directed by the study doctor. Placebo Cream applied topically, twice daily, for 12 weeks, once in the morning and once in the evening, anywhere the patient would apply their ordinary body moisturizer except atopic dermatitis lesions.	Other: Placebo Cream; Drug: 0.05% Desonide Cream; Other Names: Actavis

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
SCORAD (Severity Scoring of Atopic Dermatitis)	Dermatologic assessment and scoring of atopic dermatitis lesion severity	Change from Baseline at Week 12

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
SCORAD (Severity Scoring of Atopic Dermatitis)	Dermatologic assessment and scoring of atopic dermatitis lesion severity	Change from Baseline at Week 2
SCORAD (Severity Scoring of Atopic Dermatitis)	Dermatologic assessment and scoring of atopic dermatitis lesion severity	Change from Baseline at Week 4
SCORAD (Severity Scoring of Atopic Dermatitis)	Dermatologic assessment and scoring of atopic dermatitis lesion severity	Change from Baseline at Week 8

Collaborators and Investigators

• Sponsor: Procter & Gamble Beauty
• Investigators: Principal Investigator: Adnan Nasir, MD, PhD, Wake Research Associates, LLC

Study record dates

Study Major Dates

• Study Start: March 1, 2016
• Primary Completion (ACTUAL): June 1, 2016
• Study Completion (ACTUAL): June 1, 2016

Study Registration Dates

• First Submitted: April 4, 2016
• First Submitted That Met QC Criteria: April 4, 2016
• First Posted (ESTIMATE): April 8, 2016

Study Record Updates

• Last Update Posted (ESTIMATE): October 5, 2016
• Last Update Submitted That Met QC Criteria: October 4, 2016
• Last Verified: October 1, 2016

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Skin Diseases; Immune System Diseases; Hypersensitivity, Immediate; Genetic Diseases, Inborn; Skin Diseases, Genetic; Hypersensitivity; Skin Diseases, Eczematous; Dermatitis; Dermatitis, Atopic; Anti-Inflammatory Agents; Desonide
• Other Study ID Numbers: CSD2016003

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: NO